Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DBH | P09172 | 2/20 | 1.00 |
| ▸ | MAOB | P27338 | 10/20 | 0.64 |
| ▸ | MAOA | P21397 | 8/20 | 0.64 |
| ▸ | COMT | P21964 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | BCHE | P06276 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7281446 | 1.00 | DBH (1.00) | DBHMAOBMAOACOMTMAPT | |
| SCHEMBL8848391 | 0.88 | DBH (0.79) | DBHMAOBMAOACOMTMAPT | |
| SCHEMBL8848392 | 0.88 | DBH (0.79) | DBHMAOBMAOACOMTMAPT | |
| SCHEMBL8848407 | 0.87 | DBH (0.77) | DBHMAOBMAOACOMTMAPT | |
| SCHEMBL8848409 | 0.87 | DBH (0.77) | DBHMAOBMAOACOMTMAPT | |
| SCHEMBL7245289 | 0.86 | MAOB (0.79) | DBHMAOBMAOACOMTBCHE | |
| SCHEMBL8848373 | 0.86 | DBH (0.75) | DBHMAOBMAOACOMTMEN1 | |
| SCHEMBL8848374 | 0.86 | DBH (0.75) | DBHMAOBMAOACOMTMEN1 | |
| SCHEMBL8848326 | 0.85 | DBH (0.74) | DBHMAOBMAOACOMTMAPT | |
| SCHEMBL8848323 | 0.85 | DBH (0.74) | DBHMAOBMAOACOMTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0444899-B1 | Catechol derivatives, their physiologically acceptable salts, esters and their use in the treatment of tissue damage induced by lipid peroxidation | ORION YHTYMAE OY (FI) | 1997-02-05 | — | — | EP | claimed |
| EP-0323162-B1 | NEW USE OF CATECHOL-O-METHYL TRANSFERASE (COMT) INHIBITORS AND THEIR PHYSIOLOGICALLY ACCEPTABLE SALTS AND ESTERS | ORION YHTYMAE OY (FI) | 1993-09-15 | — | — | EP | claimed |
| EP-0444899-A2 | Catechol derivatives, their physiologically acceptable salts, esters and their use in the treatment of tissue damage induced by lipid peroxidation | ORION-YHTYMÀ OY (FI) | 1991-09-04 | — | — | EP | claimed |
| US-5001152-A | Use of catechol-O-methyl transferase (COMT) inhibitors and their physiologically acceptable salts for ulcer treatment | ORION CORPORATION LTD. (FI) | 1991-03-19 | — | — | US | claimed |
| EP-0323162-A2 | New use of catechol-o-methyl transferase (comt) inhibitors and their physiologically acceptable salts and esters | ORION-YHTYMÀ OY (FI) | 1989-07-05 | — | — | EP | claimed |
| US-20030060472-A1 | Novel substituted nitrocatechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them | PORTELA & CA, SA (PT) | 2003-03-27 | — | — | US | disclosed |
| EP-1167342-A1 | Novel substituted nitrocatechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them | Portela & Ca., S.A. (PT) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001098251-A1 | NOVEL SUBSTITUTED NITROCATECHOLS, THEIR USE IN THE TREATMENT OF SOME CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PORTELA & CA SA (PT) | 2001-12-27 | — | — | WO | disclosed |
| EP-0444899-B1 | Catechol derivatives, their physiologically acceptable salts, esters and their use in the treatment of tissue damage induced by lipid peroxidation | ORION YHTYMAE OY (FI) | 1997-02-05 | — | — | EP | disclosed |
| US-5489614-A | MEDICINAL ANTIOXIDANTS USED IN PREVENTION AND TREATMENT OF TISSUE DAMAGE INDUCED BY LIPID PEROXIDATION | ORION-YHTYMA OY (FI) | 1996-02-06 | — | — | US | disclosed |
| US-5446194-A | Pharmacologically active catechol derivatives | ORION-YHTYMA OY (FI) | 1995-08-29 | — | — | US | disclosed |
| US-5283352-A | Transferase inhibitor | ORION-YHTYMA OY (FI) | 1994-02-01 | — | — | US | disclosed |
| US-5112861-A | Inhibitors of catechol-methyl-transferase enzyme, levodopa | ORION-YHTYMA OY (FI) | 1992-05-12 | — | — | US | disclosed |
| EP-0444899-A2 | Catechol derivatives, their physiologically acceptable salts, esters and their use in the treatment of tissue damage induced by lipid peroxidation | ORION-YHTYMÀ OY (FI) | 1991-09-04 | — | — | EP | disclosed |
| US-4963590-A | ENZYME INHIBITOR FOR TREATING PARKINSON'S DISEASE ALONG WITH DOPA;POTENTIATION | ORION-YHTYMA OY (FI) | 1990-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060472-A1 | Novel substituted nitrocatechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them | PMP22, NLN, CNR2 | DBH 110/4885MAOB 157/4885MAOA 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.